Alaunos Therapeutics (TCRT) Return on Capital Employed (2016 - 2025)
Historic Return on Capital Employed for Alaunos Therapeutics (TCRT) over the last 15 years, with Q3 2025 value amounting to 1.23%.
- Alaunos Therapeutics' Return on Capital Employed rose 24200.0% to 1.23% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.23%, marking a year-over-year increase of 24200.0%. This contributed to the annual value of 1.0% for FY2024, which is 100.0% down from last year.
- Alaunos Therapeutics' Return on Capital Employed amounted to 1.23% in Q3 2025, which was up 24200.0% from 1.71% recorded in Q2 2025.
- In the past 5 years, Alaunos Therapeutics' Return on Capital Employed registered a high of 0.81% during Q2 2021, and its lowest value of 4.46% during Q1 2024.
- In the last 5 years, Alaunos Therapeutics' Return on Capital Employed had a median value of 1.15% in 2025 and averaged 1.87%.
- As far as peak fluctuations go, Alaunos Therapeutics' Return on Capital Employed tumbled by -35600bps in 2024, and later skyrocketed by 26700bps in 2025.
- Over the past 5 years, Alaunos Therapeutics' Return on Capital Employed (Quarter) stood at 0.89% in 2021, then grew by 6bps to 0.84% in 2022, then plummeted by -244bps to 2.88% in 2023, then surged by 32bps to 1.96% in 2024, then surged by 37bps to 1.23% in 2025.
- Its Return on Capital Employed was 1.23% in Q3 2025, compared to 1.71% in Q2 2025 and 3.03% in Q1 2025.